NCT04747847View on ClinicalTrials.gov

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

November 30, 2024

Study Completion Date

April 30, 2025

Conditions
Kawasaki Disease
Interventions
DRUG

Atorvastatin and anakinra

Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA

Trial Locations (1)

92093

University of California San Diego, San Diego

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of California, San Diego

OTHER